The drugs haloperidol or trazodone, or behavior management techniques (BMT), are commonly used to treat agitation in Alzheimer's patients, but the first large-scale, randomized placebo-controlled study of such treatments has found that they are only marginally effective at best. The Alzheimer Disease Cooperative Study (ADCS) reports that across all groups, only 34% of patients improved relative to baseline; patients in the trazodone arm showed the greatest improvement. Agitation worsened in 46% of patients, however, and did not change in 20%. Interestingly, 31% of patients receiving placebo showed improvement. This suggested that meeting regularly with a well-trained and supportive clinician may in itself help reduce agitation.—Hakon Heimer
No Available References
No Available Further Reading
- Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ, . Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 Nov 14;55(9):1271-8. PubMed.